| 11.02 -0.43 (-3.76%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.34 |
1-year : | 14.33 |
| Resists | First : | 11.42 |
Second : | 12.27 |
| Pivot price | 11.24  |
|||
| Supports | First : | 10.05 |
Second : | 8.36 |
| MAs | MA(5) : | 11.12 |
MA(20) : | 11.07 |
| MA(100) : | 10.09 |
MA(250) : | 10.82 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 42.7 |
D(3) : | 45.1 |
| RSI | RSI(14): 51.3 |
|||
| 52-week | High : | 17.35 | Low : | 8.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DCTH ] has closed above bottom band by 23.9%. Bollinger Bands are 35.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 11.7 - 11.77 | 11.77 - 11.82 |
| Low: | 10.87 - 10.94 | 10.94 - 10.99 |
| Close: | 10.91 - 11.02 | 11.02 - 11.12 |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Fri, 22 May 2026
Is Delcath Systems Inc (DCTH) a Bargain After 3.8% Drop? GF Value Says Undervalued - GuruFocus
Fri, 15 May 2026
New Delcath hires receive 24,500 stock units over 3 years - Stock Titan
Fri, 15 May 2026
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Quantisnow
Tue, 12 May 2026
Liver cancer-focused Delcath heads to Nasdaq BioConnect investor conference May 19 - Stock Titan
Thu, 07 May 2026
Cancer treatment company targets $100M sales with 29 centers active - Stock Titan
Thu, 07 May 2026
Delcath Systems (NASDAQ: DCTH) grows Q1 2026 sales but posts small loss - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 35 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 8.1 (%) |
| Held by Institutions | 48.7 (%) |
| Shares Short | 3,550 (K) |
| Shares Short P.Month | 3,970 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.26 |
| Profit Margin | 0.6 % |
| Operating Margin | -6.6 % |
| Return on Assets (ttm) | -1 % |
| Return on Equity (ttm) | 0.5 % |
| Qtrly Rev. Growth | 26.2 % |
| Gross Profit (p.s.) | 2.25 |
| Sales Per Share | 2.61 |
| EBITDA (p.s.) | -0.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 21 (M) |
| Levered Free Cash Flow | 20 (M) |
| PE Ratio | 1102 |
| PEG Ratio | 1.6 |
| Price to Book value | 3.37 |
| Price to Sales | 4.2 |
| Price to Cash Flow | 17.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|